Patents by Inventor James M. Frincke
James M. Frincke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110212935Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: April 27, 2011Publication date: September 1, 2011Applicant: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110137057Abstract: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a condition where cell or tissue repair is needed.Type: ApplicationFiled: February 18, 2011Publication date: June 9, 2011Inventor: James M. Frincke
-
Publication number: 20110129423Abstract: The invention provides a method to identify or characterize compounds for treating cancer wherein the compounds have a capacity to decrease systemic levels of one or more cholesterol metabolites in treated mammal(s). Such compounds include 17-(3-pyridyl)androst-5,16-diene-3?,7?-diol, 17-(2-morpholinyl)-7?-ethylandrost-5,16-diene-3?-ol, 17-(2-morpholinyl)-7?-ethylandrost-5,16-diene-3?-ol-16-acetate, 17-(4-oxazolyl)-7?-ethylandrost-5,16-diene-3?-ol-16-methyl ether and 17-(4-oxazolyl)-7?-ethylandrost-5,16-diene-3?-ol. Compositions and formulations comprising the compounds and one or more excipients are also provided.Type: ApplicationFiled: November 30, 2010Publication date: June 2, 2011Inventor: James M. Frincke
-
Patent number: 7947846Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5 -ene-3?-yl)-?-D-glucopyranosiduronate, 16?,3?-dihydroxy-5?-androstan-17-one or 3,7,16,17 -tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17 -tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.Type: GrantFiled: December 8, 2009Date of Patent: May 24, 2011Assignee: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Patent number: 7935839Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: October 16, 2006Date of Patent: May 3, 2011Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110098260Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: ApplicationFiled: December 1, 2010Publication date: April 28, 2011Applicant: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110085984Abstract: The invention provides a drug product for treating radiation exposure comprising, a drug in a dosage form; and packaging for the drug together with a package insert or label that includes information about the drug's efficacy, where the information about the drug's efficacy is obtained at least in part from methods described in the disclosure.Type: ApplicationFiled: December 14, 2010Publication date: April 14, 2011Inventors: James M. Frincke, Armando Garsd
-
Patent number: 7910571Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: October 13, 2006Date of Patent: March 22, 2011Assignee: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Patent number: 7910755Abstract: The invention relates to methods to prevent, treat, ameliorate or slow the progression of one or more of a blood cell deficiency, unwanted inflammation, allergy, immune suppression condition, immunosenescence, autoimmune disorder, infection, neurological disorder, cardiovascular disorder, pulmonary disorder, trauma, hemorrhage, bone fracture or unwanted or excess bone loss with steroid compounds containing carbon-carbon double bonds within the fused four-ring system such that the steroid compounds are unsaturated. The unsaturated steroid compounds include 3,16?,17?-trihydroxy-7-acetoxy-androst-1,3,5(10),6-tetraene, 3,16?,17?-trihydroxy-7-methoxy-androst-1,3,5(10),6-tetraene, 3,17?-dihydroxy-7-acetoxy-16?-fluoro-androst-1,3,5(10),6-tetraene, 3,17?-dihydroxy-7-methoxy-16?-fluoro-androst-1,3,5(10),6-tetraene, 3,17?-dihydroxy-7,16?-diacetoxy-androst-1,3,5(10),6-tetraene and 3,17?-dihydroxy-7-methoxy-16?-acetoxy-androst-1,3,5(10),6-tetraene.Type: GrantFiled: March 25, 2006Date of Patent: March 22, 2011Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Patent number: 7906497Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: June 3, 2010Date of Patent: March 15, 2011Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110009372Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.Type: ApplicationFiled: September 30, 2009Publication date: January 13, 2011Inventor: James M. Frincke
-
Patent number: 7863261Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: January 4, 2011Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Publication number: 20100240633Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: ApplicationFiled: June 3, 2010Publication date: September 23, 2010Applicant: Harbor BioSciences, Inc.Inventors: Henry A. Lardy, Padma Marwah, James M. Frincke
-
Publication number: 20100227841Abstract: The invention provides 17?-ethynylandrost-5-ene-3?,7?,17?-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 ?U/mL.Type: ApplicationFiled: March 25, 2010Publication date: September 9, 2010Applicant: Harbor BioSciencs, Inc.Inventors: Dwight Stickney, Christopher L. Reading, James M. Frincke
-
Publication number: 20100222313Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.Type: ApplicationFiled: December 9, 2009Publication date: September 2, 2010Inventor: James M. Frincke
-
Publication number: 20100222425Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3?-yl)-?-D-glucopyranosiduronate, 16?,3?-dihydroxy-5?-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.Type: ApplicationFiled: December 8, 2009Publication date: September 2, 2010Inventor: James M. Frincke
-
Publication number: 20100222315Abstract: The invention provides 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (?30.5, ?31 or ?32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will generally have a fasting insulin level of at least 4 ?U/mL or another characteristic as described herein.Type: ApplicationFiled: March 25, 2010Publication date: September 2, 2010Applicant: Harbor BioSciencs, Inc.Inventors: Christopher L. Reading, James M. Frincke, Dwight Stickney, Jaime Flores-Riveros
-
Patent number: 7776845Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: August 17, 2010Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Patent number: 7723532Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.Type: GrantFiled: October 23, 2006Date of Patent: May 25, 2010Assignee: Harbor BioSciences, Inc.Inventors: James M. Frincke, Christopher L. Reading, Clarence N. Ahlem
-
Patent number: 7696189Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: April 13, 2010Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventor: James M. Frincke